Published in Oncogene on April 27, 2015
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol (2016) 0.91
EGF receptor ligands: recent advances. F1000Res (2016) 0.77
Sprouty2 inhibits amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells. Oncotarget (2016) 0.75
Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy. Genes (Basel) (2016) 0.75
miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway. Oncogenesis (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Autocrine secretion and malignant transformation of cells. N Engl J Med (1980) 7.49
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev (1998) 5.31
ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol (2009) 4.40
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science (1989) 3.13
Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev (2008) 2.94
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development (2005) 2.73
Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci U S A (2007) 2.32
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res (2008) 2.28
Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett (1999) 2.06
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A (2005) 2.00
Amphiregulin exosomes increase cancer cell invasion. Curr Biol (2011) 1.93
EGFR family: structure physiology signalling and therapeutic targets. Growth Factors (2008) 1.87
Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic (2009) 1.83
Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. Cell Regul (1991) 1.73
Engineering epidermal growth factor for enhanced mitogenic potency. Nat Biotechnol (1996) 1.68
Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem (2006) 1.67
Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res (2010) 1.59
The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets (2005) 1.59
Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J (1998) 1.49
Roles for growth factors in cancer progression. Physiology (Bethesda) (2010) 1.48
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) (2006) 1.43
A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J Cell Biol (2010) 1.35
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol (2012) 1.28
Systems biology of growth factor-induced receptor endocytosis. Traffic (2008) 1.26
Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest (2010) 1.23
Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem (2007) 1.20
EGF and amphiregulin differentially regulate Cbl recruitment to endosomes and EGF receptor fate. Biochem J (2008) 1.18
Essential role of c-Cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth factor receptor. Biochemistry (2009) 1.16
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem (2004) 1.14
EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors (2012) 1.13
Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol (2009) 1.12
Amphiregulin. Semin Cell Dev Biol (2014) 1.09
A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS One (2011) 1.08
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resist Updat (2011) 1.04
Affinity regulates spatial range of EGF receptor autocrine ligand binding. Dev Biol (2002) 1.01
Quantitative modeling perspectives on the ErbB system of cell regulatory processes. Exp Cell Res (2008) 1.00
Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene (2010) 0.99
Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol (2008) 0.96
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiol (2012) 0.95
Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene (2013) 0.88
New developments in the treatment of ovarian cancer--future perspectives. Ann Oncol (2013) 0.86
The EGF domain: requirements for binding to receptors of the ErbB family. Vitam Horm (2000) 0.85
A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF. PLoS One (2012) 0.85
A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene (2011) 0.84
Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. Proc Natl Acad Sci U S A (2010) 0.82
The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors. Oncogene (2015) 0.85
A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene (2011) 0.84
FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. Oncogene (2013) 0.81
MiRNA-513a-5p Inhibits Progesterone Receptor Expression and Constitutes a Risk Factor For Breast Cancer: The ORDET Prospective Study. Carcinogenesis (2017) 0.75